Ovarian cancer-associated ascites is generally considered non-beneficial for disease status. However, our group was able to identify PEDF in the acellular fraction of ascites, which shows antiangiogenic and proapoptotic effects on tumor cells. Thus, we propose inducing PEDF gene expression using the Sleeping Beauty transposon (SBT) system may potentially emerge as a new therapeutic tool in ovarian cancer treatment.